血清钙卫蛋白与补体因子C3在早期银屑病关节炎中是优于C反应蛋白的炎症生物标志物
本研究纳入67例早期未治疗银屑病关节炎(PsA)、50例早期类风湿关节炎(RA)和61名健康对照(HC),检测血清C3、钙卫蛋白(S100A8/9)和血清淀粉样蛋白A(SAA)。基线时PsA患者C3(中位数1.38 g/L)和S100A8/9(中位数5.58 µg/mL)显著高于HC且与RA相当;在CRP阴性亚组中C3和S100A8/9仍高于HC;肥胖亚组中CRP不能区分PsA、RA与HC,而S100A8/9显著高于HC,SAA及衍生炎症比值不能区分。1年后达到低疾病活动度的PsA患者C3和S100A8/9显著下降。肥胖亚组中复合标志物C3×钙卫蛋白诊断性能优于CRP(AUC=0.836)。
要点
- 早期未治疗PsA患者血清C3和钙卫蛋白(S100A8/9)显著高于健康对照,且与早期RA相当。
- 在CRP阴性亚组中,PsA患者C3和S100A8/9仍高于健康对照。
- 肥胖亚组中CRP不能区分PsA、RA与HC,而S100A8/9显著高于HC;SAA及中性粒细胞/单核细胞比值、淋巴细胞/单核细胞比值不能区分。
核心结论
- C3和钙卫蛋白在早期PsA中升高并对治疗有反应,在肥胖和CRP阴性患者中优于CRP,可能有助于改善临床诊断和疾病监测。
研究设计与样本
- 前瞻性多中心队列研究,纳入67例早期未治疗成人PsA患者,与50例早期RA患者和61名健康对照比较,使用基线和1年数据。
- 通过ELISA检测血清补体因子3(C3)、钙卫蛋白(S100A8/9)和血清淀粉样蛋白A(SAA),采用受试者工作特征曲线分析评估区分性能。
主要发现
- 基线时PsA患者C3中位数1.38 g/L和S100A8/9中位数5.58 µg/mL显著高于健康对照,且与RA相当。
- 在CRP阴性亚组中,PsA患者C3和S100A8/9较健康对照升高。
- 肥胖亚组中CRP水平不能区分PsA、RA和健康对照,而S100A8/9在PsA和RA中较健康对照显著升高,SAA及衍生炎症比值(中性粒细胞/单核细胞比值、淋巴细胞/单核细胞比值)不能区分PsA、RA或健康对照。
- 1年后达到低疾病活动度的PsA患者C3和S100A8/9显著下降。
- 肥胖亚组中复合标志物C3×钙卫蛋白诊断性能优于CRP(曲线下面积=0.836)。
关键数值与推荐
- PsA患者基线C3中位数1.38 g/L、S100A8/9中位数5.58 µg/mL,显著高于健康对照且与RA相当。
- 肥胖亚组中复合标志物C3×钙卫蛋白的曲线下面积=0.836,优于CRP。
临床怎么用
- 作者认为C3和钙卫蛋白在肥胖和CRP阴性患者中优于CRP,可能有助于改善临床实践中的诊断和疾病监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: C reactive protein (CRP) is frequently normal in psoriatic arthritis (PsA) despite active disease, complicating inflammation assessment. This study aimed to evaluate alternative biomarkers of inflammation in early PsA. METHODS: Adult patients with early, treatment-naïve PsA were enrolled in the prospective multicentre cohort and compared with early rheumatoid arthritis (RA) and healthy controls (HCs). Clinical assessments, inflammatory markers and peripheral blood counts were collected. For this study, baseline and 1-year data were used. Serum complement factor 3 (C3), calprotectin (S100A8/9) and serum amyloid A (SAA) were measured by ELISA. Discriminatory performance was evaluated using receiver operating characteristic curve analysis. RESULTS: A total of 67 PsA, 50 RA patients and 61 HC were included. At baseline, median levels of C3 (1.38 g/L) and S100A8/9 (5.58 µg/mL) were significantly elevated in PsA compared with HC and were comparable to RA. In the 'CRP-negative' subgroup, C3 and S100A8/9 were increased in PsA as compared with HC. In the obese subgroup, CRP levels did not discriminate PsA, RA and HC. However, S100A8/9 was significantly increased in PsA and RA as compared with HC, whereas SAA and derived inflammatory ratios (neutrophil/monocyte ratio, lymphocyte/monocyte ratio) did not discriminate PsA, RA or HC. After 1 year, C3 and S100A8/9 decreased significantly in PsA patients achieving low disease activity. In the obese subgroup, the composite marker C3×calprotectin demonstrated superior diagnostic performance as compared with CRP (area under the curve=0.836). CONCLUSIONS: C3 and calprotectin are elevated in early PsA and are responsive to treatment. These markers outperform CRP in obese and CRP-negative patients and may support improved diagnosis and disease monitoring in clinical practice.
引用
- Ishchenko A, Van Mechelen M, Pazmino S, et al. Serum calprotectin and complement factor C3 are superior biomarkers of inflammation in early psoriatic arthritis as compared with C-reactive protein. RMD Open. 2025. PMID: 40992787. doi:10.1136/rmdopen-2025-006019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。